Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, announced the appointment of Charles Rowland to its Board of Directors.
“I’m so pleased to welcome Charlie to our Board,” said Geoff McDonough,M.D., president and chief executive officer of Generation Bio. “Charlie brings more than 30 years of industry perspective to our work here, with especially strong financial, capital markets, and strategy experience in a variety of fields, including a strong track record in rare disease.”
Rowland is currently an independent board member and strategic advisor for multiple biotechnology companies including Blueprint Medicines and Orchard Therapeutics, and previously served as chief executive of Aurinia Pharmaceuticals. Prior to that he was the vice president and chief financial officer of ViroPharma, Inc., where he led and designed the company’s mid and long-term business strategy until it was acquired by Shire PLC. From 2006-2008, he served as executive vice president and chief financial officer, as well as interim co-chief executive officer for Endo Pharmaceuticals, where he optimized capital structure to enhance future business initiatives. Additionally, he held leadership positions at BioVail Pharmaceuticals, Breakaway Technologies, Pharmacia, Novartis and Bristol-Myers Squibb.
“Charlie is a seasoned industry executive with deep background in capital allocation and strategy,” said Jason Rhodes, a partner at Atlas Venture and a founder and chairman of Generation Bio’s Board of Directors, “We look forward to drawing on both his financial and operational expertise as we move through the next phases of growth.”
“Generation Bio is working to usher in a transformative era of genetic medicines with its unique approach to delivering gene therapy to address a wide range of rare diseases,” said Rowland. “I am delighted to join an exceptional company that is focused on transforming the lives of patients suffering from genetic diseases with a technology that is truly differentiated.”
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company’s therapies are based on its proprietary GeneWaveTM technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @generationbio.
Ten Bridge Communications